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RESEARCH ARTICLE

Perspectives of US women participating in a candidate PrEP
study: adherence, acceptability and future use intentions
K Rivet Amico1§ , Catalina Ramirez2, Margaret R Caplan3, Brooke EE Montgomery4, Jennifer Stewart5,
Sally Hodder6,7, Shobha Swaminathan8, Jing Wang9, Noshima Y Darden-Tabb2, Marybeth McCauley10,
Kenneth H Mayer11 , Timothy Wilkin12, Raphael J Landovitz3, Roy Gulick12, and Adaora A Adimora2 on behalf of
HPTN 069/A5305 Study Team and HPTN Women at Risk Committee
§

Corresponding author: K Rivet Amico, Department of Health Behavior and Health Education, 3830 School of Public Health, 1415 Washington Heights, Ann Arbor,
Michigan 48109-2029, USA. Tel: +1 810 360 8716. (ramico@umich.edu)

Abstract
Introduction: Limited data exist on acceptability of candidate pre-exposure prophylaxis (PrEP) regimens among US women.
We evaluated PrEP experiences, attitudes and future use intentions among sexually active women who completed the USbased HIV Prevention Trials Network 069/AIDS Clinical Trials Group 5305 study.
Methods: Women participated in the study between March 2013 and November 2015. We analysed computer-assisted selfinterview (CASI) surveys among 130 women and conducted in-depth interviews among a subset of 26 women from three
sites. Interviews were conducted in mid/late-2015.
Results: Most women (57%) reported very good/excellent PrEP adherence on CASI, although 21% acknowledged over-reporting adherence at least some of the time. Commitment to preventing HIV infection, a sense of ownership of the study, and
keeping pills stored in a visible location facilitated adherence. Adherence barriers included “simply forgetting” and being away
from home. Most women interviewed did not intend to use PrEP in the future because of lack of perceived need due to their
own (as opposed to their partners’) low-risk behaviour and concerns about affordability – but not because of side effects or
other characteristics of the regimens.
Conclusions: Improving HIV prevention options for US women will require access to affordable PrEP as well as expanding
women’s understanding of relationship- and community-level factors that increase their risk of acquiring HIV.
Keywords: PrEP; HIV prevention; women; United States; risk perception
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1 | INTRODUCTION
Although the number of new HIV infections in the United
States (US) has declined over the past decade, as of 2015,
women constituted almost one quarter (24%) of all people living
with HIV [1]. Until recently, HIV prevention strategies available
to women at risk of heterosexual transmission were largely limited to approaches that required male partner cooperation (i.e.
female or male condoms). Products that are safe, acceptable,
discreet and can be controlled by women are needed. Oral preexposure prophylaxis (PrEP) may be one such strategy. Randomized controlled trials (RCTs) have demonstrated that daily
oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC),
when used correctly and consistently, is highly effective for preventing HIV infection among men and transgender women who
have sex with men (MSM) [2-4], HIV-seronegative partners in
serodiscordant relationships [5], and heterosexual men and
women [6]. However, two PrEP RCTs in sub-Saharan Africa that
exclusively enrolled women [7,8] failed to demonstrate efficacy,

largely due to study drug non-adherence. A review of oral PrEP
efficacy trials in women found that drug levels consistent with
daily pill-taking were associated with protection [7], suggesting
that adherence is the critical factor influencing protective
outcomes.
Adherence, as well as attitudes and beliefs about PrEP,
among MSM in the US has received considerable attention in
the literature [8-23]. However, few studies have been published regarding attitudes towards use of PrEP among women
who have accumulated real experiences taking candidate PrEP
products [24-27]. Moreover, few PrEP demonstration projects
among US women have been planned [28], leaving a substantial at-risk population in the US largely under represented.
Despite PrEP’s promise as an HIV prevention tool for US
women, the lack of data on product acceptability and adherence in this population (especially in the setting of inconsistent
adherence demonstrated in international clinical trials) may
challenge its successful implementation for HIV prevention
among women in the US.
1
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In response to this paucity of data, we collected quantitative
and qualitative data from women participating in HIV Prevention Trials Network (HPTN) 069/AIDS Clinical Trials Group
(ACTG) 5305 study [29] to better understand reasons for
adherence and/or non-adherence to study drug, attitudes
towards PrEP and intentions to use PrEP after the end of the
study. Given the few PrEP trials involving US women and
demonstration projects seeking to involve them, the results of
this study may help develop approaches for supporting adherence in the rollout of current and future PrEP technologies.

2 | METHODS
2.1 | Clinical trial
HPTN069/ACTG5305 was a prospective, randomized, doubleblinded, multisite, safety and tolerability study of four antiretroviral regimens for HIV PrEP: (1) maraviroc (MVC) alone; (2)
MVC + emtricitabine (FTC); (3) MVC + tenofovir (TDF); and
(4) TDF + FTC (control) conducted with women in the US
between March 2013 and November 2015 [29]. As described
in detail in the presentation of primary outcomes [29], study
regimens consisted of three pills once-daily: MVC 300 mg, FTC
200 mg and TDF 300 mg, with matching placebos. HIV-seronegative women who reported a history of condomless vaginal or
anal intercourse with >1 HIV-seropositive male partner or man
of unknown serostatus within 90 days, and had adequate safety
laboratory parameters were enrolled at 12 US-based study sites
(Baltimore, MD; Boston, MA; Chapel Hill, NC; Cleveland, OH;
Los Angeles, CA; Newark, NJ; New York City, NY; Philadelphia,
PA; Pittsburgh, PA; San Juan, PR; Seattle, WA; and Washington,
DC). Participants received randomized study regimens for
48 weeks with follow-up visits at weeks 2, 4 and 8, and then
every eight weeks through week 48. At each study visit, interval
history, physical examination, safety laboratories, blood plasma
for drug levels, HIV testing and adherence counselling were performed at all study visits. Electronic drug monitoring was used
throughout the trial via a single pillbox (WisepillTM, Wisepill
Technologies, Cape Town, South Africa) containing the three
study medications.
The study protocol and the procedures for the qualitative
substudy were approved by institutional review boards at the
local institutions affiliated with each study site. A written
informed consent was obtained from all participants prior to
conduct of any study-related activities.

follow-up, and of them, 30 participants had permanently discontinued the study regimen prior to week 48. Thus, we
focused on CASI data from women with recent experiences
with the study drugs (N = 130 women on study medication).
Although the study used biological markers of adherence in a
subset of women, the current evaluation focused on selfreport data and did not seek to distinguish between those
with and without detectable drug at week 48.

2.2.1 | Analyses
Data analysis was performed for all enrolled women who completed the parent trial and had not discontinued their assigned
study regimen. CASI data were analysed using SAS 9.4 (SAS
Institute, Cary, NC). Descriptive statistics were performed to
provide a demographic profile of study participants and summarize survey responses.

2.3 | In-depth interviews
A subset of 26 women from three sites (New Jersey, New York
and North Carolina) were interviewed within two weeks of
study completion (week 48). Convenience sampling was used,
as the qualitative protocol was adopted late in the parent study
and there was no opportunity to randomly select from the small
pool of women who remained in the study. Site staff invited
study participants to join the qualitative substudy as they completed their final study assessments. Interviews were conducted
with a total of twenty-six women, which included twenty-three
who were on study drug at the end of the study and three who
had discontinued prior to study end. In contrast to CASI collected data, we retained the three who had discontinued study
drug in the interview subset of women because interviewers
could provide the opportunity to probe and unpack experiences
with study drug over the course of the study.
Interview domains in the structured interview guide included
experiences using a candidate PrEP regimen, attitudes towards
the study drug, factors contributing to product adherence or
non-adherence, HIV risk perception and intention to use PrEP
after study completion. Interviews were conducted by a trained
interviewer identified at each site and lasted an average of
1.5 hours. Participants received $75 as compensation for their
time and were reimbursed for transportation. All activities were
approved by the Institutional Review Boards at Rutgers New
Jersey Medical School (NJ), Weill Cornell Medicine (NY) and
the University of North Carolina at Chapel Hill (NC).

2.2 | Survey data
Detailed behavioural risk assessments and HIV risk perception
were assessed via computer-assisted self-interview (CASI) at
baseline and serially (every eight weeks). Attitudes towards
study drug, barriers and facilitators to adherence, and intentions to use PrEP after the study’s conclusion were measured
at week 48. Adherence-related facilitators and barriers were
identified by women using a list where they could select all
that applied.
We reviewed CASI data specific to beliefs, attitudes and
adherence among the 130 women who were on study drug at
week 48. As reported in the presentation of the primary outcomes for women in the parent study (HPTN069/ACTG5305)
[29], of 188 women enrolled, 160 (85%) completed the study

2.3.1 | Analyses
Interviews were transcribed, coded and analysed in Dedoose
7.0.23 (SocioCultural Research Consultants, Los Angeles, CA)
using a thematic framework analysis approach [30-32]. Five
trained analysts reviewed the transcribed interviews and
applied coding “frames” based on the in-depth interview (IDI)
guide. Each frame was iteratively reviewed by several members of the coding team in order to identify and document
key themes across the interview. Through this process, a
codebook was developed with detailed and nuanced definitions of key themes, supporting themes and example quotes.
Thematic codes were applied to transcripts using Dedoose.
Intercoder agreement was assessed at various points in the
2
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analysis process. Coding discrepancies were discussed by the
analysis team, the codebook revised accordingly and recoding
performed when necessary to ensure consistent application of
codes. To identify the most salient themes, code frequency
reports and coded text reports were generated.

Table 1. Characteristics among women participants in HPTN069/
ACTG5305 who completed week 48 on study regimen
All N = 130
Age

3 | RESULTS
3.1 | Participant characteristics (Table 1)
As detailed in Table 1, the median age of female respondents
who completed the parent trial on their assigned drug regimen
(N = 130) was 39 years (range: 18-61). Most were not married
(90%), had completed high school but less than a four-year college degree (82%) and were unemployed (59%). Almost threequarters of participants (74%) identified as non-White and 13%
self-reported Hispanic/Latina ethnicity. At baseline, women
reported an average of two sexual partners (SD: 9.0) in the past
month and one partner with whom a condom was not used (SD:
2). Women completing the trial on study drug were largely comparable to those who discontinued early, with the exception of
being older (39 vs. 32 years of age). Women in the interview
subset did not significantly differ from the full sample of women
in demography or behavioural characteristics.

3.2 | Computer-assisted self-interview
3.2.1 | Self-reported drug adherence
Participants reported generally high adherence at week 48. As
presented in Table 2, more than three-quarters of women
reported taking study drug most of the time (35%) or always
(44%) in the past 30 days. Most women similarly reported
their ability to take daily study medications as very good
(18%) or excellent (40%). Most women (75%) reported that
they never over-reported their adherence to study team
members; 21% reported overestimating their actual adherence intentionally some to all of the time.

3.2.2 | Barriers and facilitators to product adherence
The most commonly cited challenges to adherence (Table 3)
were “forgetting” (45%), being away from home (39%) and not
having pills available when they were scheduled to be taken
(22%). Few participants reported HIV stigma (4%), concern
about disclosing participation in the study (4%) or concerns
about side effects (8%).
Respondents identified commitment to preventing HIV
infection (63%), a sense of “ownership” of the study (38%),
and making sure pills are available (28%) and stored in a location that was easily visible to them (34%) as factors that made
adherence easier (Table 3). About a third of participants integrated pill-taking into existing routines (31%), developed
reminder strategies (23%) or kept track of dosing on their pill
boxes (13%). Twenty-six per cent of women reported concern
about HIV acquisition as facilitating adherence.

3.2.3 | Attitudes towards PrEP
Women estimated the efficacy of the study drugs (how good
the study drugs were at preventing HIV infection), on average,

Median (range)

39 (18 to 61)

Marital status
Married/civil union

13 (10%)

Dating, living with partner

27 (21%)

Dating, not living with partner
Single/divorced/widowed

15 (12%)
73 (56%)

Other

2 (2%)

Employment status
Full-time employment

30 (23%)

Part-time employment

24 (19%)

Not employed

76 (59%)

Education
<High School
High school graduate
Vocational/technical school

18 (14%)
46 (35%)
8 (6%)

Some college or two-year degree

34 (26%)

Finished college or graduate school

24 (19%)

Ethnicity – Latino
Hispanic/Latino

17 (13%)

Racea
Black or African American
White

83 (64%)
34 (26%)

Other

13 (10%)

Sexual behaviour at baseline
Vaginal sex with a man in the past month
Mean number of sex partners in the past month

106 (82%)
2 (9)

(SD)
Mean number of sex partners in the past month

1 (2)

with whom no condom was used (SD)
Sexual behaviour at week 48
Vaginal sex with a man in the past month
Mean number of sex partners in the past month

98 (75%)
2 (3)

(SD)
Mean number of sex partners in the past month

1 (1)

with whom no condom was used (SD)
a
Participants self-reported and were able to select more than one category. SD, standard deviation; HPTN, HIV Prevention Trials Network;
ACTG, AIDS Clinical Trials Group.

to be 69% out of 100%. Most participants had an overall positive opinion of PrEP. As presented in Table 4, over 75% would
recommend PrEP to others, and most (60%) believed PrEP
would be good for “anyone.”
Almost half of participants (48%) reported an increase in HIV
preventive behaviour while on study (“Since getting the study
pills, I do more to protect myself against HIV than I did before”).
In response to items asking about which prevention modalities
women felt they had the most “control” over, half of women
(50%) reported feeling they had more control over a partners’
condom use than daily PrEP; more than a quarter of women
3
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Table 2. Adherence to pre-exposure prophylaxis study drugs
reported by computer-assisted self-interview at week 48

Table 3. Barriers and facilitators for taking pre-exposure prophylaxis during HPTN069/ACTG5305 study reported by
women participants

N = 130 (%)
Adherence in past 30 days
All of the time
Most of the time
Half of the time
Some of the time
None of the time
Missing
Frequency of adherence over-reporting
Never
Some of the time
Most of the time
All of the time
Declined to answer
Ability to take study meds every day
Excellent
Very good
Good
Fair
Poor
Very poor
Declined to answer
Missing

N = 130 (%)
57
46
11
8
3
5

(44)
(35)
(7)
(6)
(2)
(4)

Factors that made it difficult to take study medicationsa
I did not have pills with me when I was supposed
I got confused by the instructions for when to take

1 (1)

the pill
I ran out of pills

2 (2)

I wasn’t able to tell when sex was going to happen
98
17
7
4
4

(75)
(13)
(5)
(3)
(3)

51
23
23
21
4
2
1
5

(39)
(18)
(18)
(16)
(3)
(2)
(1)
(4)

(29%) perceived an equal amount of control and only about
20% reported they felt more personal control over PrEP use.

3.3 | In-depth interviews (N = 26)

28 (22)

to take them

I forgot
I was worried about others thinking I have HIV

3 (2)
59 (45)
5 (4)

because they saw me taking the pill
I was worried about others knowing I was in the

5 (4)

study because they saw me taking the pill
I did not have a private place to take the pill
I was worried about or experiencing side effects

2 (2)
10 (8)

I was away from home

50 (39)

Declined to answer

17 (13)

Factors that made it easier to take study medications
I felt committed to finding a way to prevent HIV

82 (63)

I felt like it is my study

50 (38)

I kept pills available/with me when I would need

36 (28)

them
I worked pill-taking into something I do anyway

41 (32)

I got better/am good at planning for when I will and

14 (11)

will not have sex
I used a reminder strategy

30 (23)

I (or the site) marked the days of the week on my

17 (13)

pill case

3.3.1 | Experience using study product

I kept pills out where I could see them as

44 (34)

Two main themes were identified concerning women’s experiences using study products: (1) unrealized anticipated side
effects and (2) appreciation of the benefits of participating in
a study. Women anticipated side effects over time, which were
often not realized or dissipated within the first weeks of the
study. A number of participants also described the importance
of education and counselling by study staff in tempering their
concerns about possible side effects

a reminder
Other people have helped me stick to

11 (9)

Participant: I had a little bit of diarrhea. That’s it. No vomiting, no nausea, none of that. Just one day total. So it
really wasn’t bothersome at all in terms of, “I don’t want to
take this medicine because of it.”
Participant: At first, the study nurse said, “You might get
some side-effects,” and I was like, “Wait a minute. What am
I getting myself into?” and then, once I started taking it and
a week went by, I said, “Oh, okay, I see now,” and I would
take my medicine every day, every day.
Interviewer: So you were a little nervous at first.
Participant: At first, yeah, because I didn’t know how,
because she said some people, it didn’t make them feel

my regimen
I have had helpful conversations with study team

16 (12)

members
I have had helpful conversations with other

4 (3)

participants
I am scared of getting HIV
Other
Declined to answer

34 (26)
8 (6)
8 (5)

a
Participants could select more than one response. HPTN, HIV
Prevention Trials Network; ACTG, AIDS Clinical Trials Group.

right. I said, “Well, I wonder how it’s going to affect me?”.
She said, “It might not affect you the way it affect them,” so
I started taking it, and I was fine. I was okay.
Participants also described experience with the study that
were appreciated and described as beneficial, including regular
HIV testing and health monitoring.
Participant: I liked the fact that I got checked for – I got
my blood checked and everything, HIV tested.
4
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Table 4. Attitudes towards taking pre-exposure prophylaxis
(PrEP) during HIV Prevention Trials Network 069/AIDS Clinical
Trials Group 5305 reported by women participants
N = 130 (%)

phone alerts, keeping pills visible, engaging their social network to help with reminders). In addition, almost all of the
women who were interviewed valued the care they received
as research participants and expressed a desire to contribute
to HIV prevention research, although participants did not link
these factors to study drug adherence.

How good are study meds at preventing HIV (0% to 100%)
Mean (SD)

69 (28)

3.3.3 | Future use intentions

Would you recommend the PrEP medications used in this study
to others
Yes
No

98 (76)
1 (1)

Not sure

30 (23)

Declined to answer

1 (1)

Who would this kind of prevention approach be good for
Anyone

78 (60)

Most people

32 (25)

Some people

12 (9)

Only very few people
Declined to answer

6 (5)
2 (1)

Since getting the study pills I do more to protect myself against
HIV than I did before (valid N = 117)
Agree

60 (48)

Somewhat agree

14 (11)

Neither agree nor disagree

19 (15)

Somewhat disagree

4 (3)

Disagree
Declined to answer

27 (22)
1 (1)

Which prevention strategies do you feel you have more personal

Of the twenty-six women interviewed, only nine expressed
clear intentions of using PrEP after the study ended. The most
commonly cited reasons for not planning to use PrEP were (1)
low perceived HIV risk and (2) uncertainty about PrEP access
and efficacy (Table 6).
Women perceived themselves to be at low risk of HIV
acquisition, citing their own monogamy, their partner’s low risk
of acquiring or having HIV, and condom use. A few women
reported discontinuing sexual partnerships during the course
of trial, and did not feel that they would need PrEP until they
were once again sexually active. Valuation of risk appeared largely focused on women’s own (vs. partner) behaviour, with
being in a monogamous relationship often noted as evidence
for no HIV risk.
Women also expressed uncertainty about where to access
PrEP and whether it would be covered by insurance; some participants were unaware that oral PrEP with TDF/FTC was
approved by the US Food and Drug Administration for at-risk
women in the US. Women were also unsure how PrEP would fit
into their current HIV prevention strategies, whether it would
be efficacious enough to replace condoms or whether it should
be part of a combination of interventions for HIV prevention.

control over
Condoms (male or female)

65 (51)

Daily PrEP

25 (19)

Neither, same amount of control using either

37 (29)

condoms or PrEP
Declined to answer

3 (2)

Participant: I liked the fact that they gave you condoms.
And even though they don’t – I wouldn’t – I didn’t want to
get paid for it but they was like “Well we pay you anyway.”
I was like “Ok. That’s fine.” I get the money, the bus tickets
and then like I get the information. I get schooled on some
things. I really like the fact that I could learn from it.

3.3.2 | Barriers and facilitators to product adherence
Four themes concerning barriers and facilitators to study drug
adherence were identified (Table 5). Three themes described
barriers to study product adherence: (1) the impact of competing demands (e.g. family, employment, unrelated health
issues, unexpected events); (2) lack of established routine; and
(3) believing one should not dose if the “prescribed” dose time
was missed. Participants did not describe any concerns about
side effects or perceived HIV-related stigma as factors in nonadherence.
One overarching theme was identified as facilitating adherence: consciously building adherence habits (e.g. using cell

4 | DISCUSSION
Although most new HIV infections in the US are among men,
more than 7000 women received an HIV diagnosis in 2016
[1]. We used mixed methods (CASI and IDIs) to explore
acceptability of, adherence to, and intentions concerning
future use of PrEP among US women who completed a
48-week Phase II prospective, randomized, double-blinded,
multisite, safety and tolerability study of four candidate PrEP
regimens comprised of combinations of TDF, FTC, and MVC.
Women found the study regimens acceptable, but among
those interviewed a lack of perceived risk or need and concerns about affordable access limited enthusiasm for using
PrEP after the end of the study.
Women reported high levels of adherence, with most
reporting taking their study drugs most or all of the time during the previous month; however, nearly a quarter of women
acknowledged over-reporting the proportion of study medications they had taken at times. Previous studies have linked
intentional non-adherence and over-reporting adherence to
study teams as related to concerns about safety and side
effects [33-37]; however, few women in our study cited side
effects as barriers to adherence or discussed safety concerns
in interviews. Participants discussed initial apprehension about
side effects that were never realized, which may have
decreased concerns about safety over time.
Lapses in drug adherence were often explained as unintentional and due to a lack of established routines, reminder tools
5
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Table 5. Barriers and facilitators to product adherence and illustrative quotes
Theme

Quotes

Barriers
Competing Demands
Discussion that supported this theme centred around obligations that

Participant: Actually, I was actually stressed because my 18-year-old
was locked up. So, I was running back and forth to court to see what

took priority over participation in the research study, including

they were going to do with him. But it took two months. So, out of

family needs, employment, emergencies and other unplanned life

the two months, I was just stressed because I was like, “I could lose

events

my Section 8. I could be homeless.” And it was like I wasn’t really
focusing on this box right here [WISEPILL] because now I’ve got to
fuck with my livelihood. You get what I’m saying?
Participant: Well, I had to stop taking ‘em because I had missed my
cycle. . . Once I missed my cycle, I already knew something wasn’t
right. So I was like, “Okay, I gotta be pregnant.” So I stopped. And the
reason why I stopped, because I really didn’t know if I was going to
keep my baby or terminate my baby.
Participant: I got hit by a van – during this study, and I didn’t take my
medicine because I was in the hospital, and Susana [study nurse] was
like, “What’s going on?” The phone was going and everything, so once
I got out of the hospital, I came over here and let them know what
happened, and I didn’t take the medicine for, like, five days.

Lack of Established Routine
Women discussed a lack of established routine, including changes in

Participant: At the beginning when I had the little box [WISEPILL] with
me. . . .But I think it’s because I usually look at it and it was just like a

daily schedule, employment-related events and long-term travel or

box. So I need to remember the pills was in there – I don’t know. But

moving. Although these events often resulted in only one or two

at the beginning was real hard for me to stay on track with taking

missed pills, some women reported that unanticipated events

the pills. But once the months went by and I got used to it, like, it

caused them to miss follow-up clinic visits, leading to longer
periods of non-adherence

was routine.”
Participant: [I] just totally forgot because I’m not used to it. . .. I missed
Tuesday, I missed Wednesday. That’s when I said you know what, I’ve
got to think of another way because I can’t remember. I have a
problem with memory so I need it to be in my sight. When I wake up,
[yawns], there’s the pill box: “Oh shit, there’s my pills, got to take
them.”

Not Dosing if Dose Time was Missed
Some women reported not dosing when they missed their specific

Participant: Oh shit. I can’t take them now it’s after 12 o’clock.

dose time, suggesting that some did not understand that they
could take pre-exposure prophylaxis any time during the day
Facilitators
Consciously Building Adherence Habits
Discussion that supported this theme centred around developing
new routines and pill-taking reminders. This included using
technology (cell phones, alarm clocks), keeping pills in a visible
location as well as developing routines for pill – taking individually
or in conjunction with others

Participant: But you could set your timer on the phone, but when
you’re not used to taking pills, it’s kinda hard. You forget. But once
you start being in the study for a long time, you’ll start taking them
more regularly.
Participant: I knew that I had to take them. So, when I get up I eat and
I’ll just take the pills – I knew I had to take it because I was – I’m in
the research, so I knew I had to take it. So, I’d just wake up in the
morning and eat and just take them.
 said, “Did you take your
Participant: Yeah, and sometimes my fiance
medicine this morning?” and I was like, “Yes, I took it,” because he has
diabetes so he takes his medicine, so I would take mine. He’d be like,
“Take your medicine,” and I was like, “I’m taking it,” so he would take
his medicine and I would take mine.
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Table 6. Themes about pre-exposure prophylaxis (PrEP) future use intentions, and illustrative quotes
Theme
Low perceived HIV risk

Quotes
Participant: I don’t need them no more. . . I only have one partner and I’ve been with my partner for four
years, so – it’s a female. . . .When I was messing with men, I used condoms.
Participant: Right now, no, just because I have one partner and he – I don’t know. Maybe if I switched my life
around a little bit but right now I don’t think [so] just because I don’t feel like my risk is very high.
Participant: Yeah, I’d use it. I’m [in] an intimately, good relationship now, so I don’t really foresee that
changing. But, you know, you never know. And you never really know your partner’s full history, I guess,
unless you, you know, make them give them a medical report or something, so I’m pretty confident about
the one I have now, but, you know, what could happen later you just don’t – you can’t predict.

Uncertainty about PrEP access
and efficacy

Interviewer: Mm-hmm. So it’s [PrEP] something that you would use. So do you think you would use it by itself
or part of another prevention. . . plan, so to speak?
Participant: I think it would be the primary one. But I can also see, you know, using condoms.
Interviewer: Okay. Okay. All right. And any idea as to where you might could get PrEP today?
Participant: Well, I’m not sure if you can get it as PrEP. . . I don’t think it’s been approved for that yet. But
hopefully, you know, after this it will be.
Participant: That’s a good question. I don’t know. I . . . I don’t think that I’m in like a risk bad enough for me to
take it. And I’d also have to – I guess we didn’t talk about – I never mentioned cost. I guess that would be a
really good
Interviewer: Part two of that question is do you know where you would go and get it, like your provider or –
how much it costs or anything.
Participant: No, I wouldn’t even know how to start. So I guess that’s also the facilitation, the question before,
talking to your doctor about it, talking to your pharmacy about it, and then just having the money to
actually do it.
Participant: Yeah, as long as I could – my insurance would – but I know condoms the best way to prevent
HIV. But it wouldn’t be bad to take that pill.
Interviewer: So if your insurance covered it, you think it would be something you would look into?
Participant: Yeah.
Interviewer: And you say you still would use condoms?
Participant: Yes.
Interviewer: Okay. Are you planning to use PrEP at some point in the near future?
Participant: No. [Laughter]
Interviewer: Why wouldn’t you use PrEP?
Participant: I mean I wouldn’t even know how to get it. . .
Interviewer: Like where to go, where to get it from?
Participant: Yeah. Yeah. No idea.
Participant: I think I would trust it. I mean depending on how the outcomes look and how effective it is. I
mean I think that alone could be effective enough for preventing HIV if it’s comparable to condoms or
things like that. I mean total, I would also want a contraception or, you know, some way to prevent other
STDs. So it would be in combination with other things too.

and competing demands. Several women also reported the
(erroneous) belief that a dose could or should not be taken if
the exact “prescribed” dose time was missed. In CASI and
interviews, facilitators for taking pills included developing
habits, such as keeping pills visible, and a commitment to HIV
research and to the study. The impact on adherence of developing habits and using reminder tools is well described in the
ART (and other) adherence literature [38-41], and further
underscored by our findings. These results highlight the
importance of verifying patients’ understanding about the timing of medications and what to do when doses are inadvertently missed or taken late.
Women had generally positive impressions of PrEP after
participating in the study and believed PrEP would be a useful

HIV prevention tool and “good for anyone,” with a majority
indicating they would recommend it to others. However, some
women in the interviews expressed uncertainty about using
PrEP in the future because they were unsure about how PrEP
would fit into their current prevention strategies and whether
it would be accessible through insurance. In fact, several
women seemed unaware that an FDA-approved PrEP regimen
was available to at-risk women in the US. Intentions for PrEP
uptake may have been higher if the study actively transitioned
participants to PrEP prescribers in the local area. But the
major reason for women’s relative lack of interest in using
PrEP after the study was their perception that they were not
at risk for HIV acquisition. Discourse concerning participants’
valuation of risk was focused almost exclusively on the
7
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participant’s behaviour – with little attention to the influence
of partner characteristics and community HIV infection rates.
Although women in our study may have accurately assessed
their likelihood of acquiring HIV, their assessments could also
have missed important external factors that elevated their
risk, such as community-level HIV risk. We do note that
women, generally, did appear to report generally low HIV risk
(condomless sex, number of partners) behaviours; however,
future research should carefully consider associations between
reported behaviour and valuation of HIV risk for women
specifically. A more holistic discourse about HIV risk and risk
perception that includes partner, community and structural
influences may be particularly important for women’s uptake
of PrEP in communities that are highly impacted by HIV.
Although our study was conducted in the US, this recommendation may generalize widely; women’s unique vulnerabilities
to HIV are worldwide [42] and campaigns that focus on individual risk factors may promote an underestimate of HIV risk
for women.
Surprisingly, women did not appear to consider PrEP as a
prevention strategy that was more under their control than
condoms. Because condom use often requires women to
negotiate with partners or otherwise rely on partner initiated
behaviours and PrEP is self-directed and can be administered
without partner awareness [43], we had anticipated that
most women would rate PrEP as more in their immediate
control than condom use. The most commonly selected
response to this item was perceiving more control over condom use. This may have been influenced by the study context
– which involved taking a study drug under evaluation; where
as they can visually see a condom being used and are confident in its function, they cannot see the study drug “working”
and do not know if it is actually effective. Additionally,
women were counselled on use of condoms throughout the
study, with more than half reported that participation in the
study increased their use of prevention strategies over time.
Thus, this finding should be re-examined in the context of
open-label (known to be effective), easily accessible, PrEP
projects.
Findings should also be interpreted in the light of several
limitations. First, only a small number of study participants at
three sites were asked to participate in IDIs, thus may not be
representative of the women in the overall study. Second,
HPTN069/ACTG5305 trial participants were healthy volunteers in a blinded trial; women not engaging in research may
differ from those who do in concerns about safety and challenges with intentional non-adherence. Additionally, while eligibility criteria required participants to be at-risk for HIV (i.e.
condomless vaginal or anal intercourse with ≥1 HIV-infected
or unknown-serostatus man within 90 days of enrolment),
they were not necessarily at high risk for HIV infection.
Finally, study drug adherence and related attitudes towards
the drug and the regimen may dramatically differ from adherence and attitudes towards drugs known to be effective and
widely available outside of a study context. Study participants
completed interviews in late 2015. Efforts to increase PrEP
awareness and access for women has increased in a number
of regions in the US since that time, although PrEP uptake
remains generally low. Nonetheless, women in our study may
differ in terms of PrEP knowledge, awareness and attitudes
from more contemporary samples [44].

Strengths of this study include a study population that is
racially and ethnically similar to that of women living with HIV
in the United States, with significant representation from
Black and Hispanic women. Additionally, study sites were
broadly representative of US major cities and geographically
reflect US regions most affected by the HIV epidemic.

5 | CONCLUSIONS
Women’s valuation of their personal risk for HIV infection will
be critical to PrEP’s success as an HIV prevention strategy for
women. Building women’s demand for PrEP may be challenged
by their personal risk assessments in settings where individual-level risk factors appear minimal but contextual and partner-level factors confer elevated risk for HIV. More holistic
thinking about women’s HIV risk will be needed to maximize
the effectiveness of PrEP as an HIV prevention strategy for
women in the US.
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